Technoderma Medicines Completes Phase 1 Dose Escalation Clinical Trial of TDM-180935 for Atopic Dermatitis
- Written by PR Newswire
CHENGDU, China, Dec. 4, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD). This first clinical trial in the AD program included single dose...